BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Style Narratives: A Survey of \Patterns and Styles Assessed\ Design- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- Instructions to Expand Your Advantages from an Open Record Reward
- Eleven Creations And Developments That Steered History
- Unsold Rams May Be Less expensive Than You Suspect
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
- You finally got a doctor's appointment. Here's how to get the most out of it
